CNN: One of the leading coronavirus vaccine trials is currently paused. Prominent vaccine researchers say that's unusual
UC expert says phase III trials typically don't pause
Recently, one of the major trials being conducted for a COVID-19 vaccine was paused because a study volunteer had what's known as an "adverse event." Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine was interviewed by CNN for a story on the pause in the AstraZeneca COVID-19 vaccine trial.
Carl Fichtenbaum, MD, of the UC College of Medicine Division of Infectious Diseases. Photo/Joseph Fuqua III/UC Creative + Brand
Fichtenbaum said it was uncommon for a pause to happen in a phase III trial.
According to Fichtenbaum, "Phase 3 trials don't typically pause. I've only seen it handful of times in my experience."
Read the entire story here.
Fichtenbaum was also featured in a story on vaccine trial volunteers aired by several Hearst television stations, including WCVB in Boston.
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Stay up on all UC's COVID-19 stories, read more #UCtheGood content, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.